In this view, some drugs currently used for treating acute angioedema attacks (e.g., the B2R antagonist icatibant) or for LTP (e.g., the plasma kallikrein inhibitor lanadelumab) may target the bradykinin-driven pulmonary edema observed in COVID-19 [24,25]. Here, KNG1 is linked to COVID-19.